Parasitological, Histopathological and Regulatory Micro RNA Assessment in Chronic Murine Toxoplasmosis Treated with Bee Venom | ||||
Egyptian Journal of Veterinary Sciences | ||||
Articles in Press, Corrected Proof, Available Online from 17 March 2025 PDF (1.03 MB) | ||||
Document Type: Original Article | ||||
DOI: 10.21608/ejvs.2025.343507.2552 | ||||
![]() | ||||
Authors | ||||
Mai A. Moubarak ![]() ![]() ![]() | ||||
116th Samir Morsy street, Nasr City, Cairo,Egypt | ||||
2Theodor Bilharz research Institute, Giza,Egypt | ||||
3Faculty of Medicine, Cairo University | ||||
4Theodor Bilharz Research Institute, Giza,Egypt | ||||
5Department of Medical Parasitology, Faculty of Medicine, Cairo University, Egypt. | ||||
Abstract | ||||
This research aimed to compare the potential anti-toxoplasma impact of Bee venom (B.v.) against the commercial drug spiramycin (SPI) on chronic toxoplasmosis parasitologically. A histopathological evaluation of the me49 infection was performed on the brain, liver, and lungs. Host regulatory microRNAs miR-712-3p and miR-146b-5p were measured before and after the tested drugs were administered in the sera of Swiss albino mice. Group A served as the control group, subdivided into 4 subgroups, while Group B was further separated into four me49 infected subgroups. When compared to the positive control, the combination of B.v. and SPI had the best outcomes, with a statistically significant 94.1% reduction in brain cyst count. Me49 infection resulted in a significant rise in the level of miR-712-3p expression in rats’ serum. Furthermore, after infection, there was a 50-fold rise in miR-146b-5p in host sera. Following the tested medications' treatment of the diseased mice, these levels dropped. | ||||
Keywords | ||||
Toxoplasma; Me49 strain; Bee venom; Spiramycin; miR-712-3p; miR-146b-5p; Histopathology; Mice | ||||
Statistics Article View: 87 PDF Download: 56 |
||||